Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, +5

The Journal of Dermatology

Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (<scp>UNCOVER</scp>‐J)

Yukari Okubo, Tomotaka Mabuchi, Keiji Iwatsuki, +4

Journal of the European Academy of Dermatology and Venereology

Long‐term efficacy and safety results from an open‐label phase <scp>III</scp> study (<scp>UNCOVER</scp>‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

Yoshinori Umezawa, Hitoe Torisu‐Itakura, Yoji Morisaki, +4

Journal of the European Academy of Dermatology and Venereology

Transmissibility of asymptomatic COVID-19: Data from Japanese clusters

Ko Nakajo, Hiroshi Nishiura

International Journal of Infectious Diseases

Efficacy and safety of 40 mg or 60 mg duloxetine in <scp>J</scp>apanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study

Hitoshi Yasuda, Nigishi Hotta, Masato Kasuga, +6

Journal of Diabetes Investigation

Assessing Interventions against Coronavirus Disease 2019 (COVID-19) in Osaka, Japan: A Modeling Study

Ko Nakajo, Hiroshi Nishiura

Journal of Clinical Medicine

Trends in the prevalence and incidence of Crohn’s disease in Japan and the United States

Ko Nakajo, Michiyo Yamazaki, Hsingwen Chung, +2

International Journal of Colorectal Disease